Juno challenges validity of patent for Pfizer's pain drug Dynastat

Juno challenges validity of patent for Pfizer’s pain drug Dynastat

Intellectual Property 2019-11-12 9:44 pm By Christine Caulfield | Melbourne

Please login to bookmark

Australian drug maker Juno Pharmaceuticals has hit back at claims it is infringing the patent for US-based Pfizer’s post-operative pain killer Dynastat, saying the patent is invalid.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au